Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis

Next Previous
Trial Profile

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Neurogenic bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTENT2
  • Sponsors Ipsen

    • Most Recent Events

    • 01 Jan 2023 Results of a pooled analysis from two clinical studies: CONTENT1 and CONTENT2 assessing efficacy and safety of abobotulinumtoxinA according to etiology of neurogenic detrusor overactivity incontinence published in the Neurourology and Urodynamics
    • 01 Aug 2022 Results assessing the efficacy and safety of abobotulinumtoxinA (aboBoNT-A) for NDOI from two trials (CONTENT1, NCT02660138; CONTENT2, NCT02660359) assessing published in the European Urology
    • 09 Jun 2022 According to an Ipsen media release, result published in European Urology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top